Preferencje help
Widoczny [Schowaj] Abstrakt
Liczba wyników
2008 | 3 | 3 | 327-331
Tytuł artykułu

Detection and identification of atypical quetiapine metabolite in urine

Treść / Zawartość
Warianty tytułu
Języki publikacji
Quetiapine fumarate (Seroquel®) is an atypical antipsychotic dibenzothiazepine derivative. Due to its extensive hepatic metabolism and low level of unchanged excretion (< 1%) the routine toxicological drug-screening analyses of urine often leads to false negative results. In the present study, we report that a newly identified metabolite of quetiapine, N-desalkylquetiapine, can be used as an indicative marker of quetiapine-intake in urine using common GC-MS screening procedure. The structure of the mentioned metabolite was solved from the mass-spectrum obtained and the quetiapine presence was proved by consequent HPLC plasma analysis.
Słowa kluczowe

Opis fizyczny
  • Clinic of Emergency Toxicology and Allergology, Military Medical Academy, 3 G. Sofiiski Str, 1603, Sofia, Bulgaria
  • Laboratory of Bioinorganic and Bioanalytical Chemistry, Department of Analytical Chemistry, Faculty of Chemistry, Sofia University, 1 J. Bourchier Ave., 1164, Sofia, Bulgaria,
  • [1] Goldstein J., Arvanitis L. A., ICI 204,636 (Seroquel): A dibenzothiazepine atypical antipsychotic, Review of preclinical pharmacology and highlights of Phase II clinical trials, CNS Drug Rev., 1995, 1, 50–73[Crossref]
  • [2] Arvanitis L. A., Miller B. G., Multiple fixed doses of ’seroquel’ (quetiapine) in patients with acute exacerbation of schizophrenia: a comparison with haloperidol and placebo. The Seroquel Trial 13 study Group, Biol. Psychiatry, 1997, 2, 233–46
  • [3] Caccia S., New antipsychotic agents for schizophrenia: Pharmacokinetics and metabolism update, Curr. Opin. Invest. Drugs, 2002, 3, 1073–1080
  • [4] De Vane C. L., Nemeroff C. B., Clinical Pharmacokinetics of Quetiapine: An Atypical Antipsychotic, Clin. Pharmacokinet., 2001, 40, 509–522[Crossref]
  • [5] Hasselstrom J., Linnet K., In vitro studies on quetiapine metabolism using the substrate depletion approach with focus on drug-drug interactions, Drug Metabol. Drug Interact., 2006, 21, 187–211 [PubMed]
  • [6] Flammia D. D., Valouch T., Venuti S., Tissue distribution of quetiapine in 20 cases in Virginia, J. Anal. Toxicol., 2006, 30, 287–292 [Crossref]
  • [7] Hopenwasser J., Mozayani A., Danielson T. J., Harbin J., Narula H. S., Posey D. H., et al., Postmortem Distribution of the Novel Antipsychotic Drug Quetiapine, J. Anal. Toxicol., 2004, 28, 264–268 [Crossref]
  • [8] Langman L. J., Kaliciak H. A., Carlyle S., Fatal overdoses associated with quetiapine, J. Anal. Toxicol., 2004, 28, 520–525 [Crossref]
  • [9] Saracino M. A., Mercolini L., Flotta G., Albers L. J., Merli R., Raggi M. A., Simultaneous determination of fluvoxamine isomers and quetiapine in human plasma by means of high-performance liquid chromatography, J. Chromatogr. B, 2006, 843, 227–233[Crossref]
  • [10] Mandrioli R., Fanali S., Ferranti A., Raggi M. A., HPLC analysis of the novel antipsychotic drug quetiapine in human plasma, J. Pharm. Biomed. Anal., 2002, 30, 969–977[Crossref]
  • [11] Anderson D.T., Fritz K.L..Quetiapine (Seroquel®) concentrations in seven postmortem cases, J. Anal. Toxicol., 2000, 24, 300–304 [Crossref]
  • [12] Davis P. C., Wong J., Gefvert O., Analysis and pharmacokinetics of quetiapine and two metabolites in human plasma using reversed-phase HPLC with ultraviolet and electrochemical detection, J. Pharm. Biomed. Anal., 1999, 20, 271–282[Crossref]
  • [13] Schulz M., Schmoldt A., Therapeutic and toxic blood concentrations of more than 800 drugs and other xenobiotics, Pharmazie, 2003, 58, 437–474
Typ dokumentu
Identyfikator YADDA
JavaScript jest wyłączony w Twojej przeglądarce internetowej. Włącz go, a następnie odśwież stronę, aby móc w pełni z niej korzystać.